CRDF News and Press, Cardiff Oncology Inc. From 10/20/20

Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance -- Trial on track to meet prespecified criteria for success on its primary endpoint, with 31% (8/26) disease control rate in e...

The market got excited over the efficacy data of onvansertib, Cardiff’s Plk1 inhibitor in mCRC recently. We need to keep in mind that mltiple Plk1 inhibitors have failed multiple cancer indications in the past decade. Onvansertib’s Phase Ib/II efficacy data in mCRC m...

Onvansertib along with FOLFIRI and Avastin in a phase 1b/2 study treating second-line KRAS-mutated mCRC patients achieved a 45% objective response rate. Response rate for second-line KRAS-mutated mCRC patients remains low for standard of care treatment at roughly around 4%. Positi...

Shares of Cardiff Oncology (NASDAQ: CRDF) were skyrocketing 21.1% higher as of 3:07 p.m. EDT on Thursday. The big jump came after Piper Sandler analyst Joseph Catanzaro initiated coverage on the stock with an overweight rating. Catanzaro also set a price target for Cardiff of $25, w...

CTI BioPharma (CTIC) +130% as company to file US application for pacritinib for thrombocytopenia.Yunji (YJ) +28% after company reported RMB87.5M in GMV and 10.7M views during its live streaming show.Jiayin Group (JFIN) +18% on acquisition of 35% equity interest i...

Cardiff Oncology (CRDF) has priced its public offering of 6.5M common shares at $13.50/share, for expected gross proceeds of ~$88M.Underwriters' over-allotment is an additional 975K shares. Net proceeds will be used for development of product candidates, working capital and general corporate ...

Cardiff Oncology Prices Public Offering PR Newswire SAN DIEGO, Sept. 29, 2020 SAN DIEGO , Sept. 29, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the...

Cardiff Oncology (CRDF) has announced an underwritten public offering of its common shares. Volume, price are yet to be determinedUnderwriters have an option to purchase up to an additional 15% shares. For further details see: Cardiff Oncology readies equity offering

Cardiff Oncology Announces Proposed Public Offering PR Newswire SAN DIEGO, Sept. 29, 2020 SAN DIEGO , Sept. 29, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat canc...

Gainers: Houston American Energy (HUSA) +245%.U.S. Energy (USEG) +167%.Greenpro Capital (GRNQ) +39%.Adial Pharmaceuticals (ADIL) +34%.Innodata (INOD) +33%.Digimarc (DMRC) +30%.VOC Energy Trust (VOC) +26%.New Concept Energy (GBR) +26%.Cardiff Oncology (CRDF) +22%.Novus Capital (...